compound-10

NFAT:AP-1 inhibitor-10 is a novel inhibitor of the NFAT:AP-1:DNA interaction on the ARRE-2 element, binding to DNA in a sequence-selective manner and inhibiting the transcription of the Il2 gene and several other cyclosporin A-sensitive cytokine genes important for the effector immune response.

MINA53 inhibitor 是 MINA53 的抑制剂。

Compound 1080-0560 是一种有用的有机化合物，可用于生命科学领域的相关研究，其产品编号为 T100886。

Compound 1080-0561 是一种有用的有机化合物，可用于生命科学领域的相关研究，其产品编号为 T93832。

Compound 1080-0568 是一种有用的有机化合物，可用于生命科学领域的相关研究，其产品编号为 T101208。

Compound 1056090(SC) 是一种筛选化合物，在生命科学相关研究中具有广泛的应用。

Terbogrel 是一种可口服的 、具有选择性 thromboxane A2 受体拮抗剂（IC50 约为 10 nM），是一种 thromboxane A2 synthase 抑制剂（IC50 约为 10 nM）。Terbogrel 是一种抗血小板化合物，可抑制血小板聚集，是预防血栓的潜在化合物。

IRAK4-IN-10 是一种高效的 IRAK4 抑制剂（IC50：1.5 nM），具有潜在的抗癌和抗炎活性。IRAK4-IN-10 阻断 MyD88 信号传导，可用研究自身免疫性疾病和癌症。

Milataxel is an orally bioavailable taxane with potential antineoplastic activity. Upon oral administration, milataxel and its major active metabolite M-10 bind to and stabilize tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2 M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, milataxel appears to be a poor substrate for the multidrug resistance (MDR) membrane-associated P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).This compound is unstable in powder form and other related salt forms are recommended.

DCZ3301是一种新的芳基胍抑制剂。

Chlamydia pneumoniae-IN-1 是一种对衣原体有抑制作用的苯并咪唑类化合物，在低浓度下即可对肺炎衣原体产生抑制作用。Chlamydia pneumoniae-IN-1 具有抗菌活性，对CV-6菌株的 MIC 为12.6 μM，可用于研究肺部感染。

NO-prednisolone (NCX-1015) 是一种有效刺激体内IL-10产生的化合物，是一种释放一氧化氮(NO)的Prednisolone 衍生物。

1-Aminocyclopropane-1-carboxylic acid (ACC) 是内源性代谢产物的一种。

Irinotecan Hydrochloride (CPT-11 hydrochloride) 是喜树碱半合成衍生物的盐酸盐，是一种拓扑异构酶 I 抑制剂，可研究结肠癌和直肠癌。

SU11652 is a potent cell-permeable pyrrole-indolinone compound. SU11652 acts as an ATP-competitive tyrosine kinase receptor and angiogenic inhibitor with greater selectivity for PDGFR-β (PDGFRβ, IC50 = 3 nM), Flk-1 (VEGFR2, IC50 = 27 nM), FGFR1 (IC50= 170

10-FTHF is a donor of formyl groups in anabolism used as a substrate in formyltransferase reactions, which is important in purine biosynthesis.This compound is unstable in powder form and other related salt forms are recommended.

Ensartinib (X-396) is a potent and dual ALK MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. The ability of Ensartinib (X-396) to inhibit the growth of different cancer cell lines harboring ALK fusions or point mutations is tested. Ensartinib is potent in H3122 lung cancer cells harboring EML4-ALK E13;A20 (IC50: 15nM). Ensartinib is also potent in H2228 lung cancer cells harboring EML4-ALK E6a b; A20 (IC50: 45 nM). Furthermore, X-376 is potent in SUDHL-1 lymphoma cells harboring NPM-ALK (IC50: 9 nM). X-376 also inhibits SY5Y neuroblastoma cells harboring ALK F1174L, MKN-45 gastric carcinoma cells harboring MET dependent, HepG2 cells and PC-9 lung cancer cell lines harboring EGFR exon 19 del with IC50s of 68 nM, 156 nM, 9.644 μM and 2.989 μM, respectively[1]. The effects of Ensartinib (X-396) in vivo against H3122 xenografts are examined. A pharmacokinetic study reveals that Ensartinib shows substantial bioavailability and moderate half-lives in vivo. Nude mice harboring H3122 xenografts are treated with Ensartinib at 25mg kg bid. Ensartinib significantly delays the growth of tumors compared to vehicle alone. In the xenograft experiments, Ensartinib appears well-tolerated in vivo. Mouse weight is unaffected by Ensartinib treatment. Drug-treated mice appear healthy and do not display any signs of compound related toxicity. To further assess potential side effects of Ensartinib, additional systemic toxicity and toxico-kinetic studies are performed in Sprague Dawley (SD) rats. Following 10 days of repeated oral administration of Ensartinib at 20, 40, 80 mg kg in SD rats, all animals survive to study termination. The no significant toxicity (NST) levels are determined to be 80mg kg for Ensartinib. At NST levels, Ensartinib achieves an AUC of 66 μM×hr and a Cmax of 7.19 μM[1]. [1]. Lovly CM, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinaseinhibitors. Cancer Res. 2011 Jul 15;71(14):4920-31.

(20R)-Ginsenoside Rg3 (20(R)-Propanaxadiol) 是一种人参根中的化合物，具有抑制血管内皮细胞增生（IC50= 10 nM）和抗肿瘤作用。

Dihydrocapsaicin (CCRIS1589) 是一种天然来源的辣椒素，是TRPV1的选择性激动剂，同时可以增加 p-Akt 水平。它可以增强低温诱导的神经保护。

FLT3-IN-10 (2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl-) (compound 7c) 是有效的 FMS 样酪氨酸激酶 3 (FLT3) 抑制剂。FLT3-IN-10 具有治疗 FLT3 突变的急性髓性白血病 (AML) 的潜力。

Compound PDK0269作为5-HT3受体激动剂(3-100 μM, pEC50 5.05±0.06)，可急性增加XII(舌下)发作频率和规律性，并降低发作 次。Phenylbiguanide 产生剂量依赖性(10-500 μM)的多巴胺释放增加(280-2000%)。当Ringer 溶液中加入5 μM 的 nomifensine 时，Compound PDK0269对多巴胺释放的影响得到改善或抑制。

Falnidamol (BIBX 1382) 是一种具有口服活性的，选择性的 EGFR 酪氨酸激酶抑制剂，IC50 为3 nM。Falnidamol 对 ErbB2 (IC50=3.4 μM) 和其他一系列相关酪氨酸激酶 (IC50>10 μM) 的选择性 >1000倍。Falnidamol 是嘧啶-嘧啶化合物，具有抗癌活性。

N-Acetyltyramine 是一种群体感应抑制剂，由溶藻弧菌 M3-10 产生。N-Acetyltyramine 可以抑制C. violaceumATCC 12472 的群体感应。它可以逆转阿霉素耐药白血病 P388 细胞的耐药性。

Irinotecan-d10 Hydrochloride 是 Irinotecan Hydrochloride 的氘代化合物。Irinotecan Hydrochloride 的 CAS 号为 100286-90-6。Irinotecan Hydrochloride 是喜树碱半合成衍生物的盐酸盐，是一种拓扑异构酶 I 抑制剂，可研究结肠癌和直肠癌。